Breast Cancer Risk Investigation in Grown-up Hodgkin Lymphoma Patients Treated With MBVD.
Breast Cancer Risk Investigation in Grown-up Hodgkin Lymphoma Patients Treated With MBVD.
This is a multicenter retrospective cohort study conducted at the Hematology Unit of the University of Naples Federico II and the Hematology Department of AORN Cardarelli, Naples, Italy. The study investigates the incidence of breast cancer in adult female patients (aged ≥18 years) diagnosed with classical Hodgkin lymphoma (HL) and treated with at least one cycle of MBVD chemotherapy (liposomal doxorubicin [NPLD], bleomycin, vinblastine, dacarbazine). All diagnoses are made according to the WHO Classification of Lymphoid Neoplasms.
Ethics and Consent:
The study will be conducted in accordance with the principles of the Declaration of Helsinki. All participants will provide written informed consent for data collection and analysis. Approval by the local Institutional Ethics Committee will be obtained prior to data collection.
Study Objectives:
The primary aim is to evaluate the incidence of secondary breast cancer in female HL survivors treated with NPLD-based chemotherapy (MBVD). The potential association between NPLD and breast cancer risk has not been comprehensively studied in adult HL survivors. This study seeks to address this gap by analyzing long-term outcomes in a well-defined patient population. The target sample size is a minimum of 200 patients.
Data Collection and Study Timeline:
Eligible patients undergoing hematological follow-up at the two participating institutions will be invited to participate. Upon consent, data will be extracted from patient records and entered into standardized case report forms (CRFs). The expected duration of data collection is approximately 2 months. The observational window spans from January 2000 to July 2025.
Therapeutic Regimen:
All patients received at least one cycle of the MBVD regimen, which includes:
NPLD (Myocet™) 25 mg/m² IV on days 1 and 15, every 28 days
Bleomycin 10 mg/m² IV on days 1 and 15, every 28 days
Vinblastine 6 mg/m² IV on days 1 and 15, every 28 days
Dacarbazine 375 mg/m² IV on days 1 and 15, every 28 days
The cumulative NPLD dose remained well below the cardiotoxicity threshold of 785 mg/m². End-of-treatment evaluation included a total-body FDG-PET scan.
Radiotherapy and Supportive Therapy:
Consolidative radiotherapy (30 Gy) was administered to patients with bulky disease at diagnosis (defined as nodal mass >5 cm). All patients received standard antimicrobial prophylaxis:
Oral trimethoprim-sulfamethoxazole 960 mg (160+800 mg) twice weekly
Oral acyclovir 800 mg daily from the first day of chemotherapy until one month after the last cycle Additional supportive treatments were administered at the discretion of the treating physician.
Follow-Up and Imaging:
FDG-PET/CT was performed for staging, at the end of therapy, and subsequently every 3-6 months. PET results were interpreted using the Deauville Score (DS) and Lugano criteria:
Negative PET: DS ≤3
Positive PET: DS 4 or 5
Cardiac Monitoring:
All patients underwent comprehensive cardiac assessment, including baseline, interim, and end-of-treatment (EoT) 2D echocardiography and speckle-tracking echocardiography (STE). Additional cardiac evaluations were performed within six months of completing antineoplastic therapy.
Expected Outcomes:
The study aims to assess the long-term breast cancer risk associated with NPLD-containing regimens in HL patients, a population in which long-term toxicities remain under-investigated. The results may inform future recommendations on post-treatment surveillance and guide oncologic decision-making in young adult HL patients.
Inclusion Criteria:
Histologically confirmed diagnosis of classical Hodgkin lymphoma (HL)
Female sex
Age ≥18 years at the time of diagnosis
Treatment with ≥1 cycle of MBVD chemotherapy regimen
ECOG Performance Status (PS) 0-3
HIV negative status
Signed informed consent to participate in the study and for data analysis
Exclusion Criteria:
Incomplete or inadequate breast cancer surveillance work-up (i.e., lacking appropriate breast imaging such as ultrasound, mammography, MRI, or cytologic/histologic assessment if clinically indicated)
Last HL-related therapy (of any line) received within 5 years from the last hematological follow-up visit